Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

The Massachusetts-based company said that third-quarter revenue from its Spikevax shot came in at $1.8 billion, with $1.2 billion of the sales coming in the United States. The overall figure ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

The lawsuits specifically concern Moderna’s COVID-19 vaccine, Spikevax, and its more recently approved mRNA shot for respiratory syncytial virus (RSV), mRESVIA. GSK claims Moderna is marketing ...

Moderna earned US$6.7 billion (S$8.7 billion) in revenue from Spikevax last year. Pfizer made US$11.2 billion from sales of Comirnaty, the Covid vaccine it developed with German partner BioNTech.

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...

Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of its and BioNTech's vaccine Comirnaty. Sales of both vaccines declined significantly last ...

According to GSK, the technology used in Moderna’s vaccines, including its Spikevax family of vaccines, is based on a platform created by the team led by vaccinologist Christian Mandl.

The study, published in ACS Nano, analysed 156 blood samples from 19 individuals over 28 days after receiving a Moderna SPIKEVAX mRNA booster immunisation. The team discovered key insights into ...